Cameron Durrant, Humanigen CEO (Columbia University Technology Ventures via YouTube)

With failed NIH Covid-19 study, Hu­mani­gen CEO points to com­peti­tors' flops be­fore FDA nods

Hu­mani­gen is go­ing back to the draw­ing board for its an­ti­body meant to thwart so-called cy­tokine storms as the drug has failed an NIH Covid-19 ther­a­peu­tics study.

Cit­ing the rise in Covid-19 cas­es and deaths, as well as the need for vari­ant-ag­nos­tic treat­ments, CEO Cameron Dur­rant told End­points News the biotech will like­ly look to ex­ter­nal­ly-fund­ed plat­form stud­ies of its drug, lenzilum­ab, go­ing for­ward in the hopes of get­ting the drug to pa­tients out­side of clin­i­cal tri­als, de­spite al­ready be­ing told no by the FDA last Sep­tem­ber for an EUA re­quest.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.